What gets missed when trials are designed around data
Somewhere this morning, someone drove 40 minutes to a clinic for a trial visit they are quietly reconsidering. They signed the consent form and even showed up for the first few appointments. Yet, somewhere between the second blood draw and the third phone call they did not expect, the weight of it started to outpace the hope that brought them in.
Today’s trial teams will look at the data and see a retention problem, when what they are actually seeing is a human one.
The instinct, when retention softens and screen failure rates climb, is to look at logistics. Maybe it’s to adjust the visit schedule, add a decentralised element, or offer travel reimbursement. These are reasonable responses; however, they are also incomplete ones.
This article aims to shed light on the top three things that drive them out the door from the emotional weight of saying yes, the overwhelm of the participation itself, or perhaps the real-life cost of showing up. Read on to understand what your data may not be telling you and how you can begin to fix it.
The Emotional Weight of Saying Yes
Clinical trials are designed as scientific instruments. They are structured around hypotheses, endpoints, and statistical power. For the person reading the consent form at a kitchen table after dinner, however, the decision to participate is rarely scientific. It is personal, and in most cases, it is driven by something the protocol was never designed to account for: hope.
Hope as the real motivator
Informed consent documents are careful to explain that a trial may offer no direct benefit. The language likely says something along the lines of: This is for research, Participation contributes to future understanding, or maybe it’s that the individual will receive a placebo. That framing is clinically and ethically necessary. It is also, for many participants, beside the point. Because a person living with a serious condition who agrees to take part in a trial is, in nearly every case, hoping that something will help them. They are hoping the investigational treatment works, their condition stabilises, or that they feel better.
Research into participant reasons for dropout confirms that the personal “fit” of a trial with someone’s beliefs, preferences, and life circumstances is the strongest predictor of whether they stay or leave. When hope is met with ambiguity, or worse, with an experience that feels impersonal, participation starts to feel like a burden rather than a lifeline.
Globally, more than 80% of trials fail to enroll on time, and 55% of terminated trials cite low accrual as the primary reason. Those numbers represent people who said no or said yes and then changed their minds. The important thing here is that many of them changed their minds because the experience did not match the hope that brought them in.
What participants hear vs. what teams intend
There is a persistent translation problem in clinical research. The language that trial teams use to communicate with participants is designed for regulatory compliance and scientific accuracy. It is effective at both, but it often struggles to meet a person where they actually are.
When a coordinator explains randomisation, a participant hears uncertainty. When a protocol describes a washout period, a participant feels the loss of a treatment that was keeping them stable. When a consent form runs to forty pages, a participant absorbs the magnitude of what they are agreeing to long before they absorb the specifics. The information may all be there, but the emotional context is still missing. For additional context, we have written extensively about the role that patient centricity plays in clinical trials and the distance between what the industry means by that phrase and what patients actually experience.
The gap is real, and it matters operationally. Teams that design communication strategies around regulatory requirements without equal attention to emotional clarity are building consent processes that technically work and practically fail.
The Overwhelm of Participation
Trial protocols have become dramatically more complex over the past two decades. This complexity is driven by legitimate scientific ambition for better endpoints, richer data, and more sophisticated analyses. However, the biggest problem we’re seeing today is that the full weight of that complexity lands on the participant, and most trial teams have limited visibility into what that experience actually feels like for them.
What protocol complexity looks like at the kitchen table
The numbers are striking. IQVIA data shows that since 2005, clinical trial protocols have seen a 139% increase in procedures, a 214% rise in endpoints, and a 600% surge in data points collected per study. For the sponsor, that translates into richer datasets and stronger regulatory submissions. For the participant, it translates into more appointments, more questionnaires, more blood draws, more wearable devices, more daily diaries, and more time spent in waiting rooms.
Each of those demands is individually manageable, but in combination, they become a second job. A participant managing a chronic condition while working full-time and raising a family does not experience a 12-visit protocol the same way a trial design team does. They experience it as twelve days of rearranging childcare, explaining absences to an employer, and sitting in a clinic, wondering how long this one will take.
IQVIA’s own research confirms that protocols with higher patient burden scores correlate directly with more protocol deviations, more amendments, and longer cycle times. Avoidable amendments alone can cost sponsors an average of $453,932 per occurrence. The irony is that the complexity designed to strengthen a trial’s scientific value is actively undermining its operational viability.
The gap between clinical design and lived understanding
Clinical trials are data-point rich and aim to obtain as much information as possible, but at what cost? The cost is borne almost entirely by people who are not clinicians, who do not read protocols for a living, and who are processing complex medical information while managing their own fear and fatigue.
In fact, participants frequently cite confusion as a factor in disengagement. The real-world impact on patients in clinical trials is something we have explored in depth, and the consistent finding is the same: when participants feel informed and understood, they stay. When they feel processed, they leave.
Average dropout rates across therapeutic areas have increased by 25% over a recent seven-year period, and the overall screen failure rate has risen to 36.3%. In CNS trials specifically, screen failures have doubled, reaching 57%. These are signals of a systemic design issue and addressing them requires more than operational adjustments.
The Impact on Real Lives
“Already, I’m frustrated that the trial kit wasn’t delivered, so now I have to track it down. How do I respond/attend checks when I’ve got four teenagers on school holidays and back-to-back work meetings?”
Juggling a condition, a life, and a trial
Trial participation does not exist in isolation. It sits atop everything else a person is already managing. From their job to their family to their existing treatment regimen, the daily challenges of living with a condition that may already limit their energy, mobility, or cognitive bandwidth.
Logistical burden alone eliminates a significant portion of potential participants before recruitment even begins. Personal cost is a meaningful factor for many, and in fact, participation lasting longer than six months is consistently identified as a strong barrier to both initial enrolment and sustained retention.
The invisible dropout
Many withdrawals from clinical trials are voluntary. They are not driven by adverse events or protocol violations, but rather by a participant deciding that continuing is no longer worth it.
The conventional response is generally procedural, involving reducing visit frequency, enabling remote data collection, and simplifying patient-facing materials.
There is also growing interest in whether AI can transform the patient experience by identifying at-risk participants earlier and personalising touchpoints. While these interventions help, they do not always address the root cause, which is that the person inside the trial feels like a data point rather than a participant.
Every clinical trial sign-up represents a real person dedicating their time, effort, and daily life to a cause far greater than their own health outcome. When trial teams lose sight of that, retention strategies become mechanical. They manage logistics without addressing the human experience underneath, and the invisible dropouts continue.
What Changes When Teams Experience it For Themselves?
The three barriers outlined above share a common root. Trial teams possess deep clinical expertise, rigorous scientific training, and a genuine commitment to their work. What most of them lack is a visceral, first-person understanding of what it feels like to be on the other side of a protocol. They may know the procedures, but they have rarely sat in a clinic waiting room, wondering whether the treatment is working, or opened an envelope containing instructions they do not fully understand.
Designing trials with empathy built in
This is the precise gap that our immersive patient simulation addresses. Specifically, the Clinical Trials Day Experience puts R&D professionals, clinical operations teams, and CRO staff inside the patient experience for a full working day. Through a smartphone app that interrupts your schedule with urgent tasks, a physical kit that simulate real symptoms, and live role-play phone calls from trained actors playing healthcare professionals, participants spend 24 hours experiencing the disruption, confusion, and emotional weight that trial participants navigate every day.
From there, post-experience embedding workshops translate the insights captured throughout the experience into concrete, role-specific commitments. This way, a clinical operations lead leaves with a different perspective on visit scheduling, or a medical writer reconsiders how consent language lands on a non-clinical reader. Perhaps even a CRO project manager rethinks site communication protocols. The shift is felt, and it produces changes that show up in the numbers.
Clinical trials are among the most human activities the pharmaceutical industry undertakes. Every protocol, every endpoint, every data point exists because a real person agreed to participate. The industry that depends on their willingness has a responsibility to understand what that willingness costs them, and the most direct path to that understanding is to feel it.
Take Part in the Clinical Trials Day Experience
If your team designs, manages, or delivers clinical trials, A Life in a Day’s Clinical Trials Day Experience offers something no training module or slide deck can replicate: a genuine, first-person understanding of what trial participation feels like for the people your work depends on. Contact A Life in a Day to discuss how the experience can be tailored to your therapy area, your protocol challenges, and your team’s specific objectives, because better trials start with a better understanding of the people inside them.
Frequently Asked Questions
What are the most common reasons patients drop out of clinical trials?
The most frequently cited reasons include logistical burden (travel distance, time away from work, cost), physical discomfort from procedures or side effects, confusion about trial processes and expectations, and a feeling of being treated impersonally. Many dropouts are voluntary rather than medically necessary, driven by an accumulation of practical and emotional strain.
How does patient burden affect clinical trial outcomes?
Higher patient burden correlates directly with increased protocol deviations, more amendments, longer cycle times, and higher screen failure rates. Research shows that avoidable amendments driven by overly complex protocols cost sponsors an average of $453,932 per occurrence, and more than 80% of trials globally fail to enroll on time.
What is the A Life in a Day Clinical Trials Day Experience?
It is a 24-hour immersive simulation in which pharma and CRO professionals experience a working day as a clinical trial participant. Through a smartphone app, a physical kit of simulation items, and live role-play phone calls with trained actors, they experience the disruption, confusion, and emotional weight that real patients navigate daily.
Who is the Clinical Trials Day Experience designed for?
It is designed for anyone involved in the design, delivery, or management of clinical trials. This includes R&D teams, clinical operations, medical affairs, CRO staff, patient recruitment specialists, and L&D professionals responsible for building patient-centric capability within their organisations.
How long does the immersive experience last?
The core experience runs for up to 24 hours, woven into the participant’s normal working day. It is followed by embedding workshops where teams translate their insights into specific, role-relevant commitments and actions.
What measurable outcomes have clients seen from this experience?
In one engagement with over 200 R&D staff, 94% said the experience would lead to a more patient-centric approach to their trials. Clients have reported improved protocol designs that reduce patient burden, stronger retention strategies, and more empathetic communication with trial participants.
Can the experience be tailored to a specific therapy area or trial protocol?
Yes. A Life in a Day works with clients to design experiences grounded in real patient stories from specific conditions and therapy areas. The simulation content is developed from in-depth patient interviews and reflects the actual challenges of living with the condition relevant to the client’s trials.
How does A Life in a Day differ from traditional patient centricity training?
Traditional training delivers information through slides, workshops, or e-learning. A Life in a Day delivers understanding through lived experience. Participants do not learn about the patient perspective in the abstract. They feel it physically and emotionally, which produces a depth of insight and motivation that conventional training cannot replicate.
